When Mark Samuels took over as CEO of the British Generic Manufacturers Association in early 2021, it was something of a baptism of fire for the former Roche executive.
Forced to grapple with the combined pressures of the UK’s formal withdrawal from the EU medicines framework and the ongoing COVID-19 pandemic, the country’s off-patent industry has nevertheless managed to maintain supply and avoid shortages, he tells Generics Bulletin in an exclusive two-part